NeuroMetrix (NeuroMetrix) COGS-to-Revenue : 0.36 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix COGS-to-Revenue?

NeuroMetrix's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.47 Mil. Its Revenue for the three months ended in Dec. 2023 was $1.32 Mil.

NeuroMetrix's COGS to Revenue for the three months ended in Dec. 2023 was 0.36.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. NeuroMetrix's Gross Margin % for the three months ended in Dec. 2023 was 64.34%.

NeuroMetrix COGS-to-Revenue Historical Data

The historical data trend for NeuroMetrix's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix COGS-to-Revenue Chart

NeuroMetrix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.76

0.29

0.28

0.30

0.33

NeuroMetrix Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.33	0.31	0.32	0.35	0.36

NeuroMetrix COGS-to-Revenue Calculation

NeuroMetrix's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	1.954	/	5.901
	=	0.33

NeuroMetrix's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.47	/	1.318
	=	0.36

NeuroMetrix (NAS:NURO) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

NeuroMetrix's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.47 / 1.318
	=	64.34 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

NeuroMetrix COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroMetrix (NeuroMetrix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

4B Gill Street, Woburn, MA, USA, 01801

Website

https://www.neurometrix.com

NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.

Executives

Bradley M Fluegel	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins	officer: Chief Financial Officer
Topline Capital Management, Llc	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp	10 percent owner	544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani	director, officer: Chairman, President and CEO	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin	officer: Senior VP, Consumer	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van	director	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran	officer: S. VP and GM, International	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz	director	CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc	officer: Senior Vice President & GM
Walter Christensen	officer: Sr. VP, Global Sales	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor	director	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C)	10 percent owner	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017